Up to 70% of COPD patients are underdiagnosed.1
82% of patients with severe emphysema never see a specialist.2
Discover Olympus® SeleCT™ Screening powered by 4DMedical – the first AI-driven solution for enhanced BLVR patient identification.
As the world’s third leading cause of mortality, COPD is a serious health condition affecting millions of people.4 Unfortunately, only a fraction of those suffering from COPD may have access to interventional care in order to be properly diagnosed and treated. This makes finding qualified candidates, who may benefit from bronchial lung volume reduction treatment a real challenge. The traditional patient selection process is cumbersome, resource-intensive and time-consuming. It’s a burden for patients and physicians alike, often resulting in frustration and disappointment.
There is a better way.
SeleCT™ Screening clears an innovative path to program success by working in the background to identify promising candidates for BLVR, empowering physicians to focus on patients who are likely to qualify for the procedure.
SeleCT™ Screening’s proprietary AI algorithm analyzes all non-contrast chest CT scans
Leveraging AI, SeleCT Screening identifies potential BLVR patients based on emphysema destruction and fissure completeness scores
For patients who meet screening criteria, SeleCT Screening automatically generates quantitative CT reports
Reports that meet requirements for Spiration™ Valve therapy are forwarded to a secure patient portal for proceduralist review and analysis
A complete medical examination of identified candidates can be performed in-office to determine patient eligibility for BLVR
Over 50% of candidates are disqualified at the final step – the CT scan.3
By leveraging AI to automatically analyze CT scans as the first step in the process, SeleCT™ Screening reduces manual workups on ineligible patients and accurately identifies potential candidates with less wasted time and resources.
Percentages above reflect patients disqualified during the EMPROVE clinical trial. Twelve percent (12%) of candidates did not qualify based on other criteria.The EMPROVE clinical trial was a multicenter, open-label randomized controlled trial in which patients with severe emphysema were randomized 2:1 to receive Spiration™ Valve System therapy with medical management, or medical management alone.
*Am Respir Crit Care Med, 2019 Dec 1; 200(11): 1354-1362.
3 out of 4 patients referred for BLVR treatment are determined to be ineligible.3
For many, the path to BLVR candidacy ends in rejection and disappointment. SeleCT™ Screening may help turn false hope into real results. This streamlined approach enables physicians to diagnose and intervene sooner, while providing eligible patients an opportunity for an improved quality of life.
George Z. Cheng, MD, PhD
Interventional Pulmonologist
Dr. Cheng is a paid consultant of the Olympus Corporation, its subsidiaries, and/or its affiliates. The statements made by Dr. Cheng are based on Dr. Cheng’s experiences, thoughts and opinions and do not necessarily represent the views or opinions of Olympus. As with any product, results may vary and the techniques, instruments and settings can vary from facility to facility.
Finding the Needle in the Haystack: Redefining BLVR Patient Selection Through an Integrated AI Approach
Integrated Artificial Intelligence Screening to Optimize Patient Identification for Bronchoscopic Lung Volume Reduction Therapy: Redefining Patient Selection with SeleCT™ Screening
Endobronchial valve therapy with the Spiration™ Valve System offers patients with severe emphysema a customized, minimally invasive treatment option for lung volume reduction.
Potential complications which may be associated with bronchoscopy and/or the Spiration™ Valve System may include, but are not limited to, pneumothorax, worsening of COPD symptoms, pneumonia, dyspnea and in rare cases, death. Prior to using the Spiration Valve System, please review the full list of risks and complications at https://spirationvalve.com/potential-risks-complications for additional information on indications, contraindications, warnings, precautions and potential complications.
